Handa Pharmaceuticals (6620) reported revenue of NT$65.9 million for Oct 2026, -24.8% year on year and -6.5% from the previous month. Revenue for Jan–Oct 2026 was NT$696.3 million (-54.1% year on year).
In Oct 2026, it ranked No. 92 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$65.9 million | -24.8% | -6.5% |
| Sep 2026 | NT$70.4 million | -20.1% | +5.6% |
| Aug 2026 | NT$66.7 million | -79.9% | -4.3% |
| Jul 2026 | NT$69.7 million | +0.6% | -13.9% |
| Jun 2026 | NT$80.9 million | -21.8% | +13.5% |
| May 2026 | NT$71.3 million | -24.4% | +14.8% |
| Apr 2026 | NT$62.1 million | -88.9% | -21.1% |
| Mar 2026 | NT$78.7 million | +11.0% | +43.2% |
| Feb 2026 | NT$55 million | +4.2% | -27.4% |
| Jan 2026 | NT$75.7 million | +32.2% | -44.7% |
| Dec 2025 | NT$136.8 million | +106.5% | +80.5% |
| Nov 2025 | NT$75.8 million | +35.6% | -13.4% |
| Oct 2025 | NT$87.6 million | +34.4% | -0.6% |
| Sep 2025 | NT$88.1 million | +37.7% | -73.5% |
| Aug 2025 | NT$332.1 million | +410.9% | +379.6% |
| Jul 2025 | NT$69.3 million | -14.2% | -33.0% |
| Jun 2025 | NT$103.4 million | +23.0% | +9.8% |
| May 2025 | NT$94.2 million | +28.0% | -83.2% |
| Apr 2025 | NT$561.2 million | +870.8% | +691.4% |
| Mar 2025 | NT$70.9 million | +19.9% | +34.5% |
| Feb 2025 | NT$52.7 million | -25.3% | -7.9% |
| Jan 2025 | NT$57.3 million | -34.7% | -13.6% |
| Dec 2024 | NT$66.3 million | -41.8% | +18.5% |
| Nov 2024 | NT$55.9 million | -39.4% | -14.2% |
| Oct 2024 | NT$65.1 million | -21.6% | +1.8% |
Jan–Oct 2026 cumulative: NT$696.3 million (-54.1% YoY)
Other Biotech & Medical companies
Compare with peers: Handa Pharmaceuticals vs PEC / Handa Pharmaceuticals vs Lotus Pharm / Handa Pharmaceuticals vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
營收差異主要係114年4月及8月認列Phyrago授權相關收入所致
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16